Skip to main content

IAVI 001

Phase:
I
Status:
Completed
Strategies:
DNA
Candidates:
DNA.HIVA
Countries:
United Kingdom
Volunteers:
18
Partners:
John Warin Ward, The Churchill, Headington, Oxford, UK; Medical Research Council (MRC), Oxford, UK.

 
Study Summary:
 
This is an open-label, dose-escalation study comparing the safety and immunogenicity of an HIV-1 clade A DNA vaccine, pTHr.HIVA, in healthy volunteers at low risk of HIV infection. On Days 0 and 21, study participants will receive a single intramuscular injection of 100 micrograms of DNA in 0.5 ml or 500 micrograms DNA in 1.0 ml in the deltoid muscle of the non-dominant arm. Subjects will be followed up at 6, 12 and 18 months.